<DOC>
	<DOCNO>NCT02833714</DOCNO>
	<brief_summary>The purpose research characterize effect teriflunomide activation B-cells , well capacity modify B-cell cytokine secretion . The in-vitro identified effect teriflunomide expression B-cell activation marker , costimulatory antigen present molecule , well cytokine secretion , confirm cohort Relapsing Remitting Multiple Sclerosis ( RRMS ) patient treated medication .</brief_summary>
	<brief_title>Teriflunomide 's Therapeutic Mechanisms Action Patients With Relapsing Remitting Multiple Sclerosis .</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>confirm diagnosis RRMS accord McDonald 's diagnostic criterion , age 1855 , extend disability status score ( EDSS ) 1.55.5 . Previous treatment DMT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>